0.1883
0.26%
-0.0005
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharma talks NDA for Fibromyalgia drug, FDA decision on NDA acceptance expected December 2024 - Proactive Investors USA
Tonix Pharmaceuticals Holding (FRA:TPM0) Effect of Exchange Rate Changes : €-0.03 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference - The Manila Times
Tonix Pharmaceuticals to Present Pipeline Updates, $34M DoD Contract at NobleCon20 | TNXP Stock News - StockTitan
Monkey Pox Treatment Market Advancements Highlighted by Growth, Size & Forecast 2024-2033 - WhaTech
Tonix Pharmaceuticals Holding (STU:TPM0) Free Cash Flow : €-63.32 Mil (TTM As of Sep. 2024) - GuruFocus.com
Tonix Pharmaceuticals Holding (STU:TPM0) EV-to-Revenue : 0.99 (As of Nov. 20, 2024) - GuruFocus.com
TNXP (Tonix Pharmaceuticals Holding) Enterprise Value : $10.87 Mil (As of Nov. 20, 2024) - GuruFocus.com
Can Tonix Pharma's TNX-102 SL End The 15-Year Drug Drought In Fibromyalgia? - RTTNews
TNXPTonix Pharmaceuticals Holding Corp. Latest Stock News & Market Updates - StockTitan
Tonix Pharmaceuticals to Present at the Winter 2024 Investor Summit Virtual - The Manila Times
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology Convergence 2024 Annual Meeting - Marketscreener.com
Tonix Pharmaceuticals to Present Pipeline Updates at Winter 2024 Investor Summit | TNXP Stock News - StockTitan
TNXP (Tonix Pharmaceuticals Holding) Interest Coverage : N/A (As of Jun. 2024) - GuruFocus.com
Armistice Capital, LLC Acquires New Stake in Tonix Pharmaceutica - GuruFocus.com
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments - AccessWire
KEMRI partners with US firm Tonix Pharmaceuticals to develop mpox vaccine - The Eastleigh Voice News
Tonix reports less virulent mpox vaccine candidate - Investing.com India
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting - The Manila Times
Tonix Pharma to Present Key Fibromyalgia Drug Data, Awaits FDA Decision on Fast-Tracked Treatment | TNXP Stock News - StockTitan
Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Company's Single-Dose Mpox and Smallpox Vaccine Candidate TNX-801, in Immune-Compromised Animals - The Manila Times
Tonix's TNX-801 Vaccine Shows Breakthrough Safety Results, 1000x More Effective Than Legacy Vaccines | TNXP Stock News - StockTitan
Tonix Pharma earnings beat by $2.70, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tonix Pharmaceuticals Files FDA Application for First New Fibromyalgia Drug in 15 Years | TNXP Stock News - StockTitan
Tonix Pharma Unveils Promising TNX-1700 Cancer Data - TipRanks
Tonix presents new data on TNX-801 mpox vaccine - BioWorld Online
Tonix Pharma Partners for Vaccine Clinical Trial - Yahoo Finance
Tonix Pharmaceuticals Holding Corp. Announces Research Agreement with Kenya Medical Research Institute to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - Marketscreener.com
Tonix Pharmaceuticals Announces Research Agreement with Kenya Medical Research Institute (KEMRI) to Design, Plan and Seek Regulatory Approval for a Phase I Clinical Study of TNX-801 for Mpox in Kenya - The Manila Times
Tonix Pharmaceuticals (TNXP) Earnings Date and Reports 2024 - MarketBeat
Tonix reports promising mpox vaccine candidate data By Investing.com - Investing.com South Africa
Tonix reports promising mpox vaccine candidate data - Investing.com
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 - The Manila Times
Tonix Pharmaceuticals CEO Discusses New Drug Application for Fibromyalgia Treatment - Proactive Investors UK
Tonix Pharmaceuticals Holding (LTS:0A4T) PE Ratio (TTM) : At Loss (As of Oct. 29, 2024) - GuruFocus.com
Tonix Pharmaceuticals to Present at BIO-Europe® 2024 - StockTitan
Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference - StockTitan
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 - Yahoo Finance
Tonix Pharmaceuticals Holding (FRA:TPM0) Purchase Of Proper - GuruFocus.com
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency - Marketscreener.com
Tonix Pharma gets DoD contract for antiviral development - Investing.com
Tonix Pharma Secures Defense Contract for Antiviral Development - TipRanks
Tonix Pharma gets DoD contract for antiviral development By Investing.com - Investing.com UK
Tonix Pharmaceuticals Receives First Contract Payment from U.S. Department of Defense for Accelerated Development of Broad-Spectrum Antivirals with the Defense Threat Reduction Agency (DTRA) - The Manila Times
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance
Tonix Pharmaceuticals files NDA for fibromyalgia drug - Investing.com
Tonix Pharmaceuticals files NDA for fibromyalgia drug By Investing.com - Investing.com UK
Tonix Pharmaceuticals Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) - Yahoo Finance
Tonix Pharmaceuticals Partners with X-Chem for AI-Driven Antiviral Development - MSN
Tonix and X-Chem collaborate to accelerate broad-spectrum antiviral development - BioWorld Online
Tonix Pharma Enhances Drug Development with AI Partnership - Yahoo Finance
Tonix secures DoD contract for antiviral drug development By Investing.com - Investing.com South Africa
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):